Cholecystectomy vs EUS-guided GBD With Stone Removal

March 28, 2024 updated by: Carlos Robles-Medranda, Instituto Ecuatoriano de Enfermedades Digestivas

Cholelithiasis Management: Elective Laparoscopic Cholecystectomy vs EUS-guided Gallbladder Cholecystostomy for Gallstones Clearance

In this new era of less invasive procedures, the indications for endoscopic ultrasound (EUS)-guided gallbladder drainage (GBD) are rapidly expanding. Nowadays, the standard treatment for uncomplicated cholelithiasis (symptomatic patients not requiring hospital admission or non-surgically managed during one or more hospital admissions) is elective laparoscopic cholecystectomy.

To avoid the complications, difficulties and disadvantages of cholecystectomy, the investigators proposed a single-center study to determine the safety and effectiveness of EUS-guided GBD with electrocautery-enhanced lumen-apposing metal stent (LAMS) (Boston Scientific, Marlborough, MA, EEUU) with stone removal in patients with cholelithiasis, in comparison with the gold standard treatment, the elective laparoscopic cholecystectomy.

Study Overview

Detailed Description

Currently, elective laparoscopic cholecystectomy (LC), is the preferred management for cholelithiasis in patients with history of gallstones-related adverse events, increased risk for gallbladder cancer, or recurrent typical biliary colic. Although elective LC is a commonly performed surgery, the incidence of serious adverse events is around 2.6%. Also, post-cholecystectomy syndrome, alkaline reflux gastritis and bile duct injury are chronic and feared adverse events secondary to gallbladder removal. To avoid them, a more conservative approach need to be address. The preservation of the gallbladder permits the conservation of its physiological functions, preventing LC adverse events, with potential less recovery time.

In this scenario, the endoscopic ultrasound (EUS) with lumen-apposing metal stent (LAMS)-assisted cholecystostomy for gallstones clearance has gained popularity due its trend toward an improved safety profile. The increased on advanced endoscopy experience along with the development of new stents, tools, and delivery systems, had placed the EUS-guided cholecystostomy as a plausible alternative to elective LC for acute cholecystitis, high-risk surgical patients, or patients with a concomitant bile duct neoplasia. In those contexts, EUS-guided cholecystostomy has demonstrated similar or even less hospitalization length of stays, adverse events, readmissions and reinterventions in comparison with elective LC or percutaneous drainage, respectively. Thus, the feasibility of EUS-guided cholecystostomy for cholelithiasis deserves to be explored.

This study pursues to compare between the effectiveness and safety of EUS-guided cholecystostomy and the elective laparoscopic cholecystectomy through an interventional, two group assignment, controlled trial.

Study Type

Interventional

Enrollment (Estimated)

56

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Carlos Robles-Medranda, MD, FASGE
  • Phone Number: +59342109180
  • Email: carlosoakm@yahoo.es

Study Locations

    • Guayas
      • Guayaquil, Guayas, Ecuador, 090505
        • Recruiting
        • Instituto Ecuatoriano de Enfermedades Digestivas
        • Sub-Investigator:
          • Martha Arevalo-Mora, MD
        • Sub-Investigator:
          • Juan Alcivar-Vasquez, MD
        • Sub-Investigator:
          • Maria Egas-Izquierdo, MD
        • Sub-Investigator:
          • Miguel Puga-Tejada, MD
        • Sub-Investigator:
          • Jorge Baquerizo-Burgos, MD
        • Sub-Investigator:
          • Domenica Cunto, MD
        • Sub-Investigator:
          • Raquel Del Valle, MD
        • Sub-Investigator:
          • Hannah Pitanga-Lukashok, MD
        • Contact:
        • Principal Investigator:
          • Carlos Robles-Medranda, MD
        • Sub-Investigator:
          • Daniel Calle-Loffredo, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adults >18 years old and <89 years old
  • Adult symptomatic patients with gallstones documented by US
  • Subject is a suitable candidate for an elective laparoscopic cholecystectomy or an EUS-guided GBD
  • Patients or authorized representative give informed consent for endoscopic or surgical approach

Exclusion Criteria:

  • Patients with hepato-pancreato-biliary diseases other than gallstones (tumors, obstructions, inflammation)
  • Patients with acute cholecystitis, cholangitis or choledocholithiasis.
  • Patients with gallbladder polyps, family history of gallbladder cancer, or any other high-risk factor for gallbladder cancer
  • Patient unable to give informed consent or refuse to participate.
  • Prior biliary intervention
  • Pregnancy or nursing
  • Any other medical condition that contraindicates surgical or endoscopic procedures

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: EUS-GBD with stone clearance
Patients >18-year-old with a diagnosis of gallstones by abdominal ultrasound, will be randomly allocated to EUS-guided GBD with electrocautery-enhanced lumen-apposing metal stent (LAMS) (Boston Scientific, Marlborough, MA, EEUU) with stone clearance.
The EUS-guided cholecystostomy entails placing a 10 mm x 10 mm or 10mm x 15mm Electrocautery-Enhanced LAMS for direct cholecystoscopy with a transnasal gastroscope. Then, the cholecystostomy will be performed with an echoendoscope, assisted by fluoroscopy to allow the puncturing of the gallbladder form either the duodenal bulb (cholecysto-duodenoscopy) or the gastric antrum (cholecysto-gastrostomy). Subsequently, from the most optimal anatomic point it will be tutored with a 10mmx10mm or 10mm x 15mm LAMS to create anastomosis between the structures. Then, the stone clearance will be performed by endoscopy (basket catheters) or by cholangioscopy (mechanical lithotripsy with or without basket catheters).
Active Comparator: Elective laparoscopic cholecystectomy
Patients >18-year-old with a diagnosis of gallstones by abdominal ultrasound are randomly allocated to elective laparoscopic cholecystectomy and laparoscopic biliary exploration.
A laparoscopic biliary exploration along with an elective laparoscopic cholecystectomy will be performed by experienced laparoscopic surgeons (over 100 laparoscopic procedures yearly) by three or four-trocar technique with transection of the cystic duct and artery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Technical success after surgical and endoscopic intervention
Time Frame: Up to 6 hours
Number of patients with correct placement LAMS or uneventful competition of laparoscopic cholecystectomy along with stone clearance.
Up to 6 hours
Resolution of biliary symptoms
Time Frame: up to 12 months
Number of patients with clinical resolution based in a questionnaire for the assessment of biliary symptoms.
up to 12 months
Adverse events after the surgical procedures
Time Frame: up to 14 days
The post-surgical adverse events will be assessed by the Clavien-Dindo classification
up to 14 days
Adverse events after the endoscopic procedures
Time Frame: Up to 14 days
The post-endoscopic adverse events will be assessed by the Adverse Events Gastrointestinal Endoscopy (AGREE) Classification
Up to 14 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
30-day major complications assessment
Time Frame: up to 30 days
To assess the safety of the procedures the investigators will consider the 30-day major complication rate
up to 30 days
Re-intervention rate
Time Frame: 12-month follow-up
Number of patients that requires a re-intervention after an endoscopic or surgical procedure
12-month follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Carlos Robles-Medranda, MD, FASGE, Instituto Ecuatoriano de Enfermedades Digestivas

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 25, 2023

Primary Completion (Estimated)

October 2, 2024

Study Completion (Estimated)

November 2, 2024

Study Registration Dates

First Submitted

August 30, 2023

First Submitted That Met QC Criteria

September 7, 2023

First Posted (Actual)

September 14, 2023

Study Record Updates

Last Update Posted (Actual)

March 29, 2024

Last Update Submitted That Met QC Criteria

March 28, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cholelithiasis

Clinical Trials on LAMS placement for cholecystostomy

3
Subscribe